We recently identi®ed CGA (coding for the alpha subunit of glycoprotein hormones) as a new estrogen receptor alpha (ERa)-responsive gene in human breast tumors. Here, we assessed the relationship between CGA status (as determined by real-time quantitative RT ± PCR) and the response to tamoxifen therapy in a well-de®ned cohort of 125 ERa-positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone. CGA overexpression, observed in 37.6% of patients, was associated with good relapse-free survival (P=0.037; univariate analysis). CGA status, combined with ERBB2 status (a marker of poor outcome), was an independent predictor of the response to tamoxifen (P=0.020; multivariate analysis). CGA status, especially when combined with ERBB2 status, may thus provide useful predictive information on tamoxifen responsiveness in breast cancer. Oncogene (2001) 20, 6955 ± 6959.
time RT ± PCR quanti®cation; endocrine therapy Tamoxifen is by far the most common endocrine agent in clinical use, for all stages of breast cancer and particularly for postmenopausal patients. Resistance to tamoxifen is a major problem. Estrogen receptor alpha (ERa) has been used to identify breast cancer patients who are likely to respond to tamoxifen, but half of all patients with ERa-positive tumors fail to respond favorably to antiestrogen treatment (McGuire, 1980) . Moreover, the proportion of ERa-positive tumors in postmenopausal patients is higher than in younger patients, meaning that ERa status is poorly predictive in this population (Diab et al., 2000) . Combined assessment of ERa and ERa-inducible genes (as markers of functional ERa-mediated cell growth mechanisms) might be more reliable. Measurement of tumor progesterone receptor (PR) and PS2 expression is slightly more reliable than ERa assay alone in this setting. However, PR and PS2 expression correlates strongly with ERa expression, meaning that the predictive information provided by these markers overlaps.
Recently, we identi®ed CGA as a new ERaresponsive gene in human breast cancer cells (BieÁ che et al., 2001) . CGA codes for the common alpha subunit of the four glycoprotein hormones hCG (human chorionic gonadotropin), LH (luteinizing hormone), FSH (follicle-stimulating hormone) and TSH (thyroidstimulating hormone). In an unselected series of breast tumors, we observed marked CGA overexpression in none of the ERa-negative tumors and in only half the ERa-positive tumors, thus dichotomizing ERa-positive patients into two subgroups of similar size (BieÁ che et al., 2001 ). This makes CGA status an attractive candidate molecular marker to predict antiestrogen responsiveness in breast cancer.
To investigate the possible relationship between CGA status and tamoxifen responsiveness, we used a realtime quantitative RT ± PCR assay to quantify CGA expression at the mRNA level in a well-de®ned cohort of 125 ERa-positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone.
We analysed tissue samples from primary breast tumors excised from 125 women at Centre ReneÂ Huguenin from 1980 ± 1994. Immediately following surgery the tumor samples were stored in liquid nitrogen until RNA extraction. The patients (mean age 70.3 years, range 53 ± 86) met the following criteria: primary unilateral non metastatic postmenopausal breast carcinoma; estrogen receptor positivity [as determined at the protein level by biochemical methods (Dextran-coated charcoal method until 1988 and thereafter EIA) and con®rmed by ERa real-time quantitative RT ± PCR assay]; complete clinical, histological and biological information available; no radiotherapy or chemotherapy before surgery; and full follow-up at Centre ReneÂ Huguenin. The standard prognostic factors are presented in Table 1 . Thirty-nine patients (31.2%) had modi®ed radical mastectomy and 86 (68.8%) had breast-conserving surgery plus locoregional radiotherapy. Patients underwent physical examinations and routine chest radiography every 3 months for 2 years, then annually. Mammograms were done annually. The median follow-up was 6.3 years (range 1.0 ± 10.0 years). All the patients received postoperative adjuvant endocrine therapy (tamoxifen, 20 mg daily for 3 ± 5 years), and no other treatment. Thirty-four patients relapsed (the distribution of ®rst relapse events was as follows: three local and/or regional recurrences, 26 metastases, and ®ve both).
The theoretical and practical aspects of real-time quantitative RT ± PCR using TaqMan methodology and the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) have been described in detail elsewhere (BieÁ che et al., 2001) . Brie¯y, total RNA extracted from frozen breast tumor tissue is reverse-transcribed before real-time PCR ampli®cation. Quantitative values are obtained from the threshold cycle number at which the increase in the signal associated with exponential growth of PCR products begins to be detected using PE Biosystems analysis software, according to the manufacturer's manuals. The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e. lack of extensive degradation) are both dicult to assess. We therefore also quanti®ed transcripts of the RPLP0 gene (also known as 36B4) encoding human acidic ribosomal phosphoprotein P0 as the endogenous RNA control, and each sample was normalized on the basis of its RPLP0 content. The relative target gene expression level was also normalized to a calibrator, or 16sample, consisting of a normal breast tissue sample. Final results, expressed as N-fold dierences in target gene expression relative to the RPLP0 gene and the calibrator, termed`Ntarget', were determined as follows:
Ntarget 2
ÁCt sample -ÁCt calibrator
where DCt values of the sample and calibrator are determined by subtracting the average Ct value of the target gene from the average Ct value of the RPLP0 gene. The nucleotide sequences of the oligonucleotide hybridization probes and primers are shown in Table 2 . To avoid ampli®cation of contaminating genomic DNA, one of the two primers was placed in a dierent exon.
To determine the cuto point for altered CGA expression at the RNA level in breast cancer tissue, CGA expression was determined in 15 normal breast tissue RNAs. As this value consistently fell between 0.4 and 6.6 (mean 1.83, Standard Deviation 1.78), values of 20 (mean+10 s.d.) or more were considered to represent CGA overexpression in breast tumor RNA samples. Moreover, with the cuto point value of 20, we previously observed a perfect match between CGA mRNA overexpression and IHC positivity (BieÁ che et al., 2001) .
Relapse-free survival (RFS) was determined as the interval between diagnosis and detection of the ®rst relapse (local and/or regional recurrence, and/or distant metastasis). Clinical, histological and biological parameters were compared using the Chi-square test. Survival distributions were estimated by the Kaplan- Meier method (Kaplan and Meier, 1958) , and the signi®cance of dierences between survival rates was ascertained using the log-rank test. Cox's proportional hazards regression model (Cox, 1972) Figure 1a ). The outcome of the 47 patients with CGA-overexpressing tumors was signi®cantly better than that of the 78 patients with normal CGA expression [5-year RFS 83.8% (78.2 ± 89.4) versus 69.3% (63.8 ± 74.8); 8-year RFS 81.3% (75.3 ± 87.3) versus 60.1% (53.7 ± 66.5)]. These data suggest that CGA overexpression is a marker of good prognosis in tamoxifen-treated postmenopausal breast cancer patients.
Most molecular studies of the response to adjuvant endocrine therapy in breast cancer have focused on the ERBB2 gene, and the results have tended to predict interest (Borg et al., 1994; TeÃ tu and Brisson., 1994, Carlomagno et al., 1996; SjoÈ gren et al., 1998) . We therefore also analysed ERBB2 expression in this series, and found that the relapse-free survival time of patients with ERBB2-overexpressing tumors was shorter than that of patients with normal ERBB2 status (P=0.00029; Table 1 ). The CCND1 gene (coding for the cyclin D1), another candidate for predicting the response to endocrine therapy, had no prognostic value in this series (Table 1) .
Two unrelated molecular markers may provide a more accurate prediction of hormone responsiveness when combined than when considered in isolation. CGA status was not related to ERBB2 status in this series (Table 3) . CGA overexpression is associated with low tumor aggressiveness, being linked to SBR histopathological grades I+II and steroid receptor positivity (BieÁ che et al., 2001) , while ERBB2 overexpression is associated with aggressive tumors, being linked to SBR histopathological grade III and steroid receptor negativity (BieÁ che et al., 1999) . Moreover, in this study, the relapse-free survival time of patients with ERBB2-overexpressing tumors was shorter than that of patients without these alterations, while that of patients with CGA-overexpressing tumors was longer. By combining CGA and ERBB2 status, we identi®ed four separate prognostic groups with signi®cantly dierent RFS curves (P=0.00029; Table 1; Figure  1b ). The patients with the poorest prognosis had What is the best technique to assess CGA status? Real-time quantitative RT ± PCR assay has a large linear dynamic range and provide accurate quantitative values. This assay is suitable for analysing the expression of genes such as CGA which show large dierences in the amount of mRNA molecules (CGA gene expression ranged from 0.2 ± 35 500 times the level in normal breast tissues) or for studying numerous molecular markers from minimal quantities of tumor samples (small early-stage tumors or cytopuncture specimens). Moreover, this standardized method has the potential for interlaboratory agreement, quality control use, and yields statistical con®dence values. We previously showed a total correlation between CGA mRNA overexpression and hCGa protein abundance (BieÁ che et al., 2001) . As speci®c antibodies directed to CGA protein are commercially available, the future applications of a CGA marker to the clinical management of breast cancer could also be done at the protein level.
Primary surgery followed by adjuvant tamoxifen alone is the common treatment for ERa-positive postmenopausal breast cancer patients. Our results show that CGA status, by evenly dichotomizing ERapositive patients, could be an attractive predictor of the response to endocrine therapy in such breast cancer patients. The predictive power of CGA status is further increased when combined with ERBB2 status. Con®rmation of the predictive value of combined CGA and ERBB2 (or CGA alone) parameters in the response to endocrine therapy in breast cancer patients needs a prospective randomized study to show that these parameters do in¯uence the outcome only in patients who received adjuvant tamoxifen as compared with untreated patients. 
